SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
NORTHWEST BIOTHERAPEUTICS, INC.
 
(Exact name of registrant as specified in its charter)
     
Delaware   94-3306718
     
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)
     
7600 Wisconsin Ave, 7th Floor
Bethesda, Maryland
 
20814
     
(Address of principal
executive offices)
  (Zip Code)
Northwest Biotherapeutics, Inc. 2007 Stock Option Plan
 
(Full title of the plan)
Alton L. Boynton, Chief Executive Officer
7600 Wisconsin Ave, 7th Floor
Bethesda, Maryland 20814
(240) 497-9024
copies to:
David H. Engvall, Esq.
Covington & Burling LLP
1201 Pennsylvania Avenue, NW
Washington, DC 20004
(202) 662-6000
 
(Name and address and telephone of agent for service)
CALCULATION OF REGISTRATION FEE
                                             
 
                  Proposed maximum     Proposed maximum        
  Title of securities     Amount to be     offering price per     aggregate offering     Amount of  
  to be registered     registered (1)     share (2)     price     registration fee  
 
Common Stock (3)
      5,480,868       $ 2.20       $ 12,057,910       $ 370.18    
 
(1) This Registration Statement shall also cover any additional shares of the Registrant’s Common Stock that become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant’s receipt of consideration which results in an increase in the number of outstanding shares of the Registrant’s Common Stock.
(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) of the Securities Act of 1933, the price per share and aggregate offering price are based upon the average closing bid and ask price of the Common Stock of the Registrant as listed on the OTC Bulletin Board on November 16, 2007.
(3) Includes associated Common Stock purchase rights.
 
 

 


 

TABLE OF CONTENTS

PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1 Plan Information.
Item 2 Registrant Information and Employee Plan Annual Information.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3 Incorporation of Documents by Reference.
Item 4 Description of Securities.
Item 5 Interests of Named Experts and Counsel.
Item 6 Indemnification of Directors and Officers.
Item 7 Exemption from Registration Claimed.
Item 8 Exhibits.
Item 9 Undertakings.
SIGNATURES
POWER OF ATTORNEY
Exhibit Index
EXHIBIT 5.1
EX-10.2
EXHIBIT 23.2
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1 Plan Information.
     A prospectus setting forth the information requested by this Item will be sent or given to participants in the 2007 Stock Option Plan as specified by Rule 428(b)(1) under the Securities Act of 1933.
Item 2 Registrant Information and Employee Plan Annual Information.
     A prospectus setting forth the information requested by this Item will be sent or given to participants in the 2007 Stock Option Plan as specified by Rule 428(b)(1) under the Securities Act of 1933.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3 Incorporation of Documents by Reference.
The following documents are hereby incorporated by reference into this Registration Statement:
     (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, filed with the Securities and Exchange Commission (the “Commission”) on April 17, 2007.
     (b) The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2007, filed with the Commission on May 15, 2007, August 20, 2007 and November 14, 2007, respectively.
     (c) The Common Stock being registered pursuant to this registration statement is part of a class of securities registered under Section 12 of the Exchange Act. A description of such securities is contained in the Company’s registration statement under the Exchange Act, including any amendment or description filed for the purpose of updating such description, and is incorporated herein by reference.
     (d) The Registrant’s Form 8-K filed with the Commission on May 21, 2007.
     (e) The Registrant’s Form 8-K filed with the Commission on June 1, 2007.
     (f) The Registrant’s Form 8-K filed with the Commission on June 4, 2007.

 


 

     (g) The Registrant’s Form 8-K filed with the Commission on June 7, 2007.
     (h) The Registrant’s Form 8-K filed with the Commission on June 18, 2007.
     (i) The Registrant’s Form 8-K filed with the Commission on June 22, 2007.
     (j) The Registrant’s Form 8-K filed with the Commission on August 29, 2007.
     (k) The Registrant’s Form 8-K filed with the Commission on October 2, 2007.
     (l) In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents.
The class of securities to be offered is Common Stock and associated rights to purchase additional Common Stock upon the occurrence of certain events.
Item 4 Description of Securities.
Not applicable. The class of securities to be offered is registered under Section 12 of the Exchange Act.
Item 5 Interests of Named Experts and Counsel.
Not applicable.
Item 6 Indemnification of Directors and Officers.
Our Certificate of Incorporation and By-Laws provide that we must indemnify to the fullest extent permitted by law any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in our right) by reason of the fact that he or she is or was one of our directors or officers or is or was serving at our request as a director or officer of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. The rights to indemnification set forth above are not exclusive of any other rights to which such person may be entitled under any statute, provision of our Certificate of Incorporation or By-Laws, agreements, vote of stockholders or disinterested directors or otherwise.
Our Certificate of Incorporation and By-Laws generally follow the language of Section 145 of the Delaware General Corporation Law (the “DGCL”) and specify certain circumstances in which a finding is required that the person seeking indemnification acted in good faith, for purposes of determining whether indemnification is available. Under our Certificate of Incorporation and By-Laws, determinations of good faith for purposes of determining whether indemnification is available are made (1) by our board of directors by a majority vote of a quorum consisting of directors who were not parties to such action, suit or proceeding, or (2) if such a quorum is not obtainable, or, if a quorum of disinterested directors so directs, by

 


 

independent legal counsel in a written opinion or (3) by the stockholders. We believe that indemnification under our Certificate of Incorporation and By-Laws covers negligence and gross negligence on the part of indemnified parties.
Pursuant to Section 145 of the DGCL, we generally have the power to indemnify our current and former directors, officers, employees and agents against expenses and liabilities that they incur in connection with any suit to which they are, or are threatened to be made, a party by reason of their serving in such positions so long as they acted in good faith and in a manner they reasonably believed to be in, or not opposed to, our best interests, and with respect to any criminal action, they had no reasonable cause to believe their conduct was unlawful. The statute expressly provides that the power to indemnify authorized thereby is not exclusive of any rights granted under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. We also have the power to purchase and maintain insurance for such persons.
The above discussion of our Certificate of Incorporation and By-Laws and Section 145 of the DGCL is not intended to be exhaustive and is qualified in its entirety by each of those documents and that statute.
The Registrant has been advised, however, that it is the position of the Commission that, insofar as such provision in the Registrant’s Certificate of Incorporation may be invoked for liabilities rising under the Securities Act, such provision is against public policy and is therefore unenforceable.
Item 7 Exemption from Registration Claimed.
Not applicable.
Item 8 Exhibits.
     
5.1
  Opinion of Counsel.
 
   
10.1
  Northwest Biotherapeutics, Inc. 2007 Stock Option Plan (Incorporated by reference to Exhibit 10.5 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 22, 2007).
 
   
10.2
  Form of Stock Option Agreement under the Northwest Biotherapeutics, Inc. 2007 Stock Option Plan.
 
   
23.1
  Consent of Counsel (Included in Exhibit 5.1).
 
   
23.2
  Consent of Independent Registered Public Accounting Firm.
 
   
24.1
  Power of Attorney (included as part of the signature page to this Registration Statement).
Item 9 Undertakings.
     The undersigned Registrant hereby undertakes:

 


 

     1. To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;
     2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;
     3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the Plan;
     4. That, for purposes of determining any liability under the Securities Act of 1933, each filing of the Company’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
     5. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
SIGNATURES
     Pursuant to the requirements of the Securities Act, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bethesda, Maryland, on November 20, 2007.
         
November 20, 2007  NORTHWEST BIOTHERAPEUTICS, INC.
 
 
  By /s/ Alton L. Boynton    
  Alton L. Boynton    
  President & Chief Executive Officer   
 
POWER OF ATTORNEY
We, the undersigned directors and officers of Northwest Biotherapeutics, Inc. (the “Company”) hereby severally constitute and appoint Alton L. Boynton, as our true and lawful attorney and agent, to do any and all things in our names in the capacities indicated below which said

 


 

Alton L. Boynton may deem necessary or advisable to enable the Company to comply with the Securities Act of 1933, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with the registration of shares of Common Stock to be granted and shares of Common Stock to be issued upon the exercise of stock options to be granted under the Northwest Biotherapeutics, Inc. 2007 Stock Option Plan, including specifically, but not limited to, power and authority to sign for us in our names in the capacities indicated below the registration statement and any and all amendments (including post-effective amendments) thereto; and we hereby approve, ratify and confirm all that said Alton L. Boynton shall do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
             
By:
  /s/ R. Steve Harris   By:   /s/ Alton L. Boynton
 
  R. Steve Harris       Alton L. Boynton
 
  Director       President and Chief Executive Officer
 
          (Principal Executive Officer) and Director
 
  November 20, 2007       November 20, 2007
 
           
             
By:
  /s/ Linda F. Powers   By:   /s/ Anthony P. Deasey
 
  Linda F. Powers       Anthony P. Deasey
 
  Chairperson of the Board       Senior Vice President of
 
          Finance and Chief Financial Officer
 
          (Principal Financial Officer
 
          and Principal Accounting
 
          Officer) and Director
 
  November 20, 2007       November 20, 2007
Exhibit Index
     
4.1
  Northwest Biotherapeutics, Inc. 2007 Stock Option Plan (Incorporated by reference to Exhibit 10.5 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 22, 2007).
 
   
5.1
  Opinion of Counsel.
 
   
10.1
  Northwest Biotherapeutics, Inc. 2007 Stock Option Plan (Incorporated by reference to Exhibit 10.5 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 22, 2007).
10.2
  Form of Stock Option Agreement under the Northwest Biotherapeutics, Inc. 2007 Stock Option Plan.
 
   
23.1
  Consent of Counsel (Included in Exhibit 5.1).
 
   
23.2
  Consent of Independent Registered Public Accounting Firm.
 
   
24.1
  Power of Attorney (included as part of the signature page to this Registration Statement).

 

 

EXHIBIT 5.1
(COVINGTON & BURLING LOGO)
November 19, 2007
Northwest Biotherapeutics, Inc.
7600 Wisconsin Avenue, N.W.
Suite 750
Bethesda, Maryland 20814
Ladies and Gentlemen:
     We have acted as counsel to Northwest Biotherapeutics, Inc., a Delaware corporation (the “ Company ”), in connection with the registration by the Company under the Securities Act of 1933, as amended (the “ Act ”), of 5,480,868 shares of the Company’s Common Stock, par value $0.001 per share (the “ Shares ”), issuable under the Company’s 2007 Stock Option Plan (the “ Plan ”), pursuant to the registration statement on Form S-8 filed with the Securities and Exchange Commission (the “ Commission ”) on the date hereof (such registration statement is herein referred to as the “ Registration Statement ”).
     We have reviewed such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion. We have assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals.
     We have assumed further that prior to the administration of the Plan by any committee of the Board of Directors of the Company (the “ Board ”), the Board will have delegated such authority to such committee by valid Board action.
     We have relied as to certain matters on information obtained from public officials, officers of the Company, and other sources believed by us to be responsible.
     Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when issued in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.
     We are members of the bar of the District of Columbia. We do not express any opinion herein on any laws other than the Delaware General Corporation Law, applicable provisions of the Delaware Constitution and reported judicial decisions interpreting these laws.

 


 

(COVINGTON & BURLING LOGO)
Northwest Biotherapeutics, Inc.
Page 2
     We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act.
Very truly yours,
/s/ Covington & Burling LLP

2

 

EXHIBIT 10.2
Northwest Biotherapeutics, Inc.
2007 Stock Option Plan
Stock Option Agreement
(Incentive Stock Option or Nonstatutory Stock Option)
     Pursuant to your Stock Option Grant Notice (“ Grant Notice ”) and this Stock Option Agreement, Northwest Biotherapeutics, Inc. (the “ Company ”) has granted you an option under its 2007 Stock Option Plan (the “ Plan ”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
     The details of your option are as follows:
      1.  Vesting. Subject to the limitations contained herein, your option will vest as provided in your Grant Notice, provided that vesting will cease upon the termination of your Continuous Service for Cause as per your Stock Option Grant Notice.
      2.  Number of Shares and Exercise Price. The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted from time to time for Capitalization Adjustments.
      3.  Exercise Restriction for Non-Exempt Employees. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended ( i.e. , a “ Non-Exempt Employee ”), you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant specified in your Grant Notice, notwithstanding any other provision of your option.
      4.  Method of Payment. Payment of the exercise price is due in full upon exercise of all or any part of your option. You may elect to make payment of the exercise price in cash or by check or in any other manner permitted by your Grant Notice, which may include one or more of the following:
           (a) Bank draft or money order payable to the Company.
           (b) In the Company’s sole discretion at the time your option is exercised and provided that at the time of exercise the Common Stock is publicly traded and quoted regularly in The Wall Street Journal , pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds.
      5.  Whole Shares. You may exercise your option only for whole shares of Common Stock.

1.


 

      6.  Securities Law Compliance. Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations.
      7.  Term. You may not exercise your option before the commencement or after the expiration of its term. The term of your option commences on the Date of Grant and expires upon the earliest of the following:
           (a) immediately upon the termination of your Continuous Service for Cause;
           (b) thirty (30) days after the termination of your Continuous Service for any reason other than your Disability or death, provided, however, that (i) if during any part of such thirty (30) day period your option is not exercisable solely because of the condition set forth in Section 6, your option shall not expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of thirty (30) days after the termination of your Continuous Service and (ii) if (x) you are a Non-Exempt Employee, (y) you terminate your Continuous Service within six (6) months after the Date of Grant specified in your Grant Notice, and (z) you have vested in a portion of your option at the time of your termination of Continuous Service, your option shall not expire until the earlier of (A) the later of the date that is seven (7) months after the Date of Grant specified in your Grant Notice or the date that is thirty (30) days after the termination of your Continuous Service or (B) the Expiration Date;
           (c) six (6) months after the termination of your Continuous Service due to your Disability;
           (d) twelve (12) months after your death if you die either during your Continuous Service or within thirty (30) days after your Continuous Service terminates;
           (e) the Expiration Date indicated in your Grant Notice; or
           (f) the day before the tenth (10th) anniversary of the Date of Grant.
     If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your option and ending on the day three (3) months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or your permanent and total disability, as defined in Section 22(e) of the Code. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than thirty (30) days after the date your employment with the Company or an Affiliate terminates.

2.


 

      8.  Exercise.
           (a) You may exercise the vested portion of your option during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular business hours, together with such additional documents as the Company may then require.
           (b) By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (1) the exercise of your option, (2) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (3) the disposition of shares of Common Stock acquired upon such exercise.
           (c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the date of your option grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option.
      9.  Transferability.
           (a) Restrictions on Transfer. Your option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during your lifetime only by you; provided, however, that the Board may, in its sole discretion, permit you to transfer your option in a manner that is not prohibited by applicable tax and/or securities laws upon your request.
           (b) Domestic Relations Orders. Notwithstanding the foregoing, your option may be transferred pursuant to a domestic relations order; provided, however , that if your option is an Incentive Stock Option, your option shall be deemed to be a Nonstatutory Stock Option as a result of such transfer.
           (c) Beneficiary Designation. Notwithstanding the foregoing, you may, by delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company, designate a third party who, in the event of your death, shall thereafter be entitled to exercise your option.
      10.  Option not a Service Contract. Your option is not an employment or service contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option shall obligate the Company or an Affiliate, their respective stockholders, Boards of Directors, Officers or Employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.

3.


 

      11.  Withholding Obligations.
           (a) At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “cashless exercise” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.
           (b) Upon your request and subject to approval by the Company, in its sole discretion, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of the option as a liability for financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.
           (c) You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein unless such obligations are satisfied.
      12.  Notices. Any notices provided for in your option or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.
      13.  Headings . The headings of the Sections in this Stock Option Agreement are inserted for convenience only and shall not be deemed to constitute a part of this Stock Option Agreement or to affect the meaning of this Stock Option Agreement.
      14.  Amendment . Nothing in this Stock Option Agreement shall restrict the Company’s ability to exercise its discretionary authority pursuant to Section 2 of the Plan; provided, however , that no such action may, without your consent, adversely affect your rights under your option.

4.


 

15. Miscellaneous.
           (a) The rights and obligations of the Company under your option shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company’s successors and assigns.
           (b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option.
           (c) You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option and fully understand all provisions of your option.
      16.  Governing Plan Document. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your option and those of the Plan, the provisions of the Plan shall control.
      17.  Choice of Law . The interpretation, performance and enforcement of this Stock Option Agreement shall be governed by the law of the state of Delaware without regard to such state’s conflicts of laws rules.

5.


 

ATTACHMENT 1
Northwest Biotherapeutics, Inc.
2007 Stock Option Plan
Notice of Exercise
     
Name
   
 
   
Address:
   
 
   
 
   
 
   
 
   
 
   
Date:
  ____________________, 20____
Northwest Biotherapeutics, Inc.
7600 Wisconsin Avenue, N.W.
Suite 750
Bethesda, Maryland 20814
Attention: [insert appropriate contact]
     By a Stock Option Agreement dated _________, 20___(the “Option Agreement”), I am the holder of an Option granted under the Northwest Biotherapeutics, Inc. 2007 Stock Option Plan (the “Plan”) to purchase up to ______ shares of Northwest Biotherapeutics, Inc. common stock (the “Shares”) at an exercise price of $______ per Share. My Option is [an Incentive] [a Nonstatutory] Stock Option.
     I hereby exercise my Option to purchase ______Shares, for which the total exercise price is $______. I have arranged to pay the exercise price as follows:
     
 
 
  I am enclosing with this notice cash, a check, a bank draft, or a money order payable to Northwest Biotherapeutics, Inc. for $______.
 
   
 
 
  With approval from the Board of Directors of Northwest Biotherapeutics, Inc. (the “Board”), pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by Northwest Biotherapeutics, Inc. or the receipt of irrevocable instructions to pay the aggregate exercise price to Northwest Biotherapeutics, Inc. from the sales proceeds;
 
   
 
 
  With approval from the Board, the following method as set forth in my
Option Agreement:
 
   
 
   
 
   
 
   
 
   
 
   

 


 

     I understand that my Option may be exercised only to the extent that it is vested, and that it will not be deemed exercised with respect to any Shares until the exercise price has been received by the [insert appropriate contact] of Northwest Biotherapeutics, Inc. (or by a person designated by the [insert appropriate contact] ).
     I understand that if I received my Option as an employee of Northwest Biotherapeutics, Inc., exercise of my Option might trigger certain federal, state, and local tax withholding obligations (although withholding will not be required with respect to exercise of an Incentive Stock Option). I have arranged to satisfy the withholding obligations by one or a combination of the following methods (to the extent permitted under my Option Agreement) and if I elected more than one method, I have specified the relative proportions below:
     
 
 
  I am enclosing with this notice a check for $______, which Northwest Biotherapeutics, Inc. has determined to be sufficient to satisfy all withholding obligations.
 
   
 
 
  I authorize Northwest Biotherapeutics, Inc. to withhold Shares with a Fair Market Value equal to the amount that must be withheld. I understand that only whole Shares will be withheld and that any fractional Shares required to be withheld will be rounded up to the next whole Share.
 
   
 
 
  I authorize Northwest Biotherapeutics, Inc. to withhold cash from an Option settled in cash equal to the amount that must be withheld.
 
   
 
  The following method as set forth in my Option Agreement:
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
Notwithstanding the provisions for withholding, I understand that I remain responsible at all times for paying any federal, state, and local income and employment taxes with respect to my Option and that Northwest Biotherapeutics, Inc. is not responsible for any liability or penalty that I incur by failing to make timely payments of tax.
         
 
  Please register my stock certificate as follows:    
 
       
Name:
       
 
       
 
       
Address:
       
 
       
 
       
 
       
 
       
 
       
Tax I.D. #:
       
 
       
     If my Option is an Incentive Stock Option, I will notify the [insert appropriate contact] of Northwest Biotherapeutics, Inc. within 30 days after any transfer of Shares acquired

2


 

pursuant to my exercise of the Option that occurs within one (1) year after the date of exercise or within two (2) years after the date the Option was granted.
     I further understand and acknowledge that my exercise of this Option and receipt of the Shares are subject to the terms and conditions of the Plan and the Option Agreement, which I have received and carefully reviewed. I understand the terms and conditions and agree to be bound by them.
         
  Sincerely,
 
 
     
  Signature   
     
 
Received by Northwest Biotherapeutics, Inc.: _________________, 20____
Approved
         
By:
       
 
     
Title:
       
 
     

3

 

EXHIBIT 23.2
(PETERSON SULLIVAN PLLC LETTERHEAD)
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement on Form S-8 of Northwest Biotherapeutics, Inc. (a development stage company) of our report dated March 27, 2007, on our audit of the balance sheets of Northwest Biotheraputics, Inc. as of December 31, 2006 and 2005, and the related statements of operations, stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2006, and for the period from March 18, 1996 (date of inception) to December 31, 2006. The Company’s financial statements for the period from March 18, 1996 (date of inception) through December 31, 2003, were audited by other auditors whose report, dated March 12, 2004, except as to Notes 1 and 12, which were as of April 26, 2004, expressed an unqualified opinion on those statements and included an explanatory paragraph that referred to substantial doubt about the Company’s ability to continue as a going concern. The other auditors’ report had been furnished to us, and our opinion, insofar as it related to the amounts included for such prior periods, was based solely on the report of such other auditors.
Our report, dated March 27, 2007, contains an explanatory paragraph that states that Northwest Biotherapeutics, Inc. has experienced recurring losses from operations since inception, has a working capital deficit, and has a deficit accumulated during the development stage. These conditions raise substantial doubt about Northwest Biotherapeutics, Inc.’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/S/ PETERSON SULLIVAN PLLC
November 16, 2007
Seattle, Washington